ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
0,897€
-0,77%
Echtzeit-Aktienkurs bluebird bio
Bid:
Ask:
Nachrichten zur bluebird bio Aktie
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
NEW YORK, April 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. – BLUE
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
ROSEN, A LONGSTANDING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
NEW YORK, April 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bluebird Bio Inc. (BLUE)
NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action…
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the bluebird…
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Bluebird biotech set to outperform pessimistic expectations
bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform pessimistic expectations regarding the launch of its Lyfgenia...…
bluebird bio set to outperform pessimistic expectations
bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform pessimistic expectations regarding the launch of its Lyfgenia...…
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence.…
bluebird bio shares slide on pricing of $125M offering, FDA hurdles
Biotech company bluebird bio Inc (NASDAQ:BLUE) has priced its underwritten public offering, making 83,333,333 shares of common stock available at…
Bluebird Bio: Aktie crasht 40 Prozent - das ist der Grund
Der Ausverkauf bei der Aktie des amerikanischen Gentherapie-Spezialisten Bluebird Bio setzt sich zur Wochenmitte fort. Mit einem Minus von gut…
Bluebird Bio: Aktie crasht 40 Prozent – das ist der Grund
Der Ausverkauf bei der Aktie des amerikanischen Gentherapie-Spezialisten Bluebird Bio setzt sich zur Wochenmitte fort. Mit einem Minus von gut…
bluebird bio stock rises on 2024 patient start guidance; commercial agreement for sickle cell therapy
bluebird bio Inc (NASDAQ:BLUE) shares took off on Thursday after the biotechnology company provided positive patient start guidance for the…
bluebird bio faces challenges despite sickle cell therapy approval
bluebird bio Inc (NASDAQ:BLUE) may have secured FDA approval for its sickle cell disease cell therapy, Lyfgenia, but market reaction has been…
Global Hemoglobinopathies Market Size To Worth USD 19.45 Billion By 2032 | CAGR of 9.5%
The Global Hemoglobinopathies Market Size was valued at USD 7.85 Billion in 2022 and the Worldwide Hemoglobinopathies Market Size is…
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Heres How
bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved…
Insiderhandel: Aufsichtsrat verkauft Aktien von Bluebird bio im Wert von 33.480$
Leschly, Nick - Aufsichtsrat - Tag der Transaktion: 2023-01-11...…
Insiderhandel: Chief Medical Officer verkauft Aktien von Bluebird bio im Wert von 4.347$
Colvin, Richard A. - Vorstand - Tag der Transaktion: 2023-01-11...…
Insiderhandel: President and CEO verkauft Aktien von Bluebird bio im Wert von 24.802$
Obenshain, Andrew - Vorstand - Tag der Transaktion: 2023-01-11...…
Insiderhandel: Chief Medical Officer verkauft Aktien von Bluebird bio im Wert von 1.398$
Colvin, Richard A. - Vorstand - Tag der Transaktion: 2022-11-04...…
Insiderhandel: President and CEO verkauft Aktien von Bluebird bio im Wert von 8.101$
Obenshain, Andrew - Vorstand - Tag der Transaktion: 2022-11-04...…